GPhA, BIO Join In Outlining Problems With House Compounding Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
The groups typically do not fall on the same side in policy fights, but say in a letter that compounding restrictions proposed in Rep. Griffith’s Compounding Clarity Act are “not that limiting.”
You may also be interested in...
News Briefs: Senate Introduces User Fee Bill; Lawsuit Ends Over Conflict Minerals
Senators try to shield FDA user fees from sequestration. Court rejects business groups’ challenge to conflict minerals reporting law. More news in brief
Track-and-Trace Bill Clears House With New Electronic Labeling Language
Safeguarding America’s Pharmaceuticals Act passes on suspension calendar, but likely sets up fight with Senate in conference.
Generics Savings Once Again Could Help A Major US Health Care Reform Bill
A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.